EARN25

Analysts React to ACADIA Trial Update

ACAD shares are flirting with a 200% YTD gain

Nov 26, 2019 at 9:32 AM
facebook X logo linkedin


It's been a huge year for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), thanks to positive updates for its drugs Nuplazid and pimavanserin, the latter of which again has the pharma name in focus. The company yesterday evening revealed mixed trial results for the drug for patients with negative symptoms of schizophrenia, with the treatment meeting its top-line goals, but failing to separate from placebo on the secondary endpoint.

In response, ACAD shares are trading down 1% at $47.29, pulling back from yesterday's four-year high of $48.27. The weak price action today comes despite bullish analyst attention, with RBC beginning coverage with an "outperform" rating and $60 price target, and Canaccord Genuity reiterated its "buy" rating and $52 price target. Oppenheimer, meanwhile, upped its price target to $48 from $44.

Most analysts are already pricing in more upside for the drugmaker, which has added almost 200% on a year-to-date basis. This is according to the average 12-month price target of $54.86, representing almost an almost 15% premium to current levels.

As for options data, peak front-month open interest is at the December 50 call, with the 55 call close behind. But while the former contract has seen almost exclusive buy-to-open activity, the latter has seen mostly sell-to-open action. From a more broader perspective, call open interest among options expiring within three months more than doubles put open interest, according to the Schaeffer's put/call open interest ratio (SOIR) of 0.47.

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!